Press Releases

 
Press Releases
  Date Title View
Mar 26, 2015
LYON, France, March 26, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the Company's participation in a major collaborative liver cancer project aimed at developing innovative new therapies for this prevalent indication. "HECAM" (HEpatocellular CArcinoma Multi-technological) ...
Mar 17, 2015
LYON, France, March 17, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the fourth quarter and year ended December 31, 2014 on Thursday, April 2, 2015, during pre-market hours. Company management will host a conference call on Thu...
Mar 9, 2015
LYON, France, March 9, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that, based on a recent meeting with the U.S. Food and Drug Administration ("FDA"), the Company plans to seek clearance of Ablatherm HIFU by way of a Direct De Novo 510(k) application as opposed to the Pre-Market A...
Feb 26, 2015
LYON, France, Feb. 26, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced a multi-national strategic OEM partnership with Quanta System, a leading manufacturer of medical lasers for surgical and other applications. Under the agreement, Quanta will manufacture customized urological stone ...
Jan 9, 2015
LYON, France, Jan. 9, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its Focal One HIFU device has been approved by Health Canada. With this approval, the Company is able to market the Focal One device for the treatment of prostate cancer in Canada. Marc Oczachowski, EDA...
Nov 20, 2014
Highlights Revenues increased 27% year-over-year to EUR 20.3 million (USD 27.4 million) for the first nine months of 2014 HIFU revenue increased 114% year-over-year during first nine months of 2014 Positive operating income, excluding FDA-related costs, for three and nine months ended September 30, 2014 S...
Nov 6, 2014
LYON, France, Nov. 6, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today received a letter from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) on its current PMA application for Ablatherm Integrated Imaging Device. The FDA letter stated that while E...
Nov 4, 2014
LYON, France, Nov. 4, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the third quarter ended September 30, 2014 on Thursday, November 20, 2014, during pre-market hours. Company management will host a conference call on Thursday, ...
Oct 21, 2014
LYON, France, Oct. 21, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale of a Focal One system to Nantes-Atlantis urology clinic, the top-ranked private prostate cancer clinic in France, and the country's only private clinic exclusively dedicated to urology. Nantes-Atla...
Oct 13, 2014
LYON, France, Oct. 13, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that data on clinical outcomes of its Ablatherm-HIFU FDA study (the "Enlight Trial") will be presented at the 4th International Symposium of the Focused Ultrasound Foundation ("FUSF"), being held October 12-14, 201...
1
... NextLast
= add release to Briefcase